Real-World Safety and Efficacy of Romosozumab in Severe Postmenopausal Osteoporosis: A Single-Centre Experience (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2953; Pres time: Nov 11, 2026; 11:30 AM - 11:45 AM; Location: W110; In Person; "In this cohort, Romosozumab had significant improvements in spinal BMD and withlessor but still significant gains at the hip. The therapy was well tolerated, with noobserved cardiovascular events in a carefully selected population.Longer follow-up is required to determine the impact on fracture reduction.Sequential antiresorptive therapy was implemented in all patients in line with currentclinical practice."
Clinical • Real-world • Real-world evidence • Cardiovascular • Musculoskeletal Diseases • Musculoskeletal Pain • Myocardial Infarction • Orthopedics • Osteoporosis • Rheumatology
|
|
Samantha Banford; John Lindsay; Paul Hamilton; Philip Wilson; Cathy Donaghy
|